Dulaglutide vs Matrixyl
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Full details →Matrixyl
Matrixyl (Palmitoyl Pentapeptide-4) is a signal peptide that stimulates collagen and extracellular matrix production. It is one of the most well-studied anti-aging peptides with proven efficacy for wrinkle reduction.
Full details →Side-by-Side Comparison
| Aspect | Dulaglutide | Matrixyl |
|---|---|---|
| Mechanism | GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression. | Mimics collagen breakdown fragments, triggering fibroblasts to produce new collagen, elastin, and other matrix components. Essentially tricks skin into repair mode without actual damage. |
| Typical Dosage | Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response. | Topical: 2-8% concentration in serums and creams. Matrixyl 3000 combines it with Palmitoyl Tetrapeptide-7 for enhanced effects. |
| Administration | Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens. | Topical application 1-2 times daily. Can be combined with other actives like retinol, vitamin C, and other peptides. |
| Side Effects | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration. | Very well-tolerated. Rare mild irritation. Suitable for sensitive skin types. |
| Best For |